Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Search Releases

News & Publications

Media Contacts
David Bricker
Phone: 832-667-5811
dmbricker@tmhs.org
 

Methodist scientists build $8.6 million imaging suite to speed diagnosis

Houston, TX - 8/17/2011

The Methodist Hospital Research Institute and Philips Healthcare are collaborating to develop new imaging technology that could be used to help identify the start -- and cause -- of an infectious disease epidemic.

King Li, M.D., radiology chair and the project's leader, and other Methodist scientists will use an $8.6 million imaging suite that includes an MRI, a PET-CT scanner, a SPECT-CT scanner, and an X-ray device called a C-arm to study patterns of tissue damage and metabolic disarray caused by different infectious disease agents -- without exposing the devices or suite rooms to the infectious agents. The suite is scheduled to be completed later this month.

Molecular imaging
Molecular imaging, like that shown here, can be used for a wide variety of purposes -- from cancer diagnosis to the tracking of infectious disease progression. Click on photo for larger version.

"The ability to have imaging suites that can handle high level infectious agents allows us to be more prepared in the community for these types of events and, more importantly, allows us to study ways to deal with their consequences," Li said.

Air-tight containment vessels make it possible for samples and infected research models to be imaged without posing risks of exposure to patients, researchers or staff. Advanced technology also allows for rapid image scanning, so that time series imagery is possible.

"No one can do longitudinal imaging studies anywhere at the moment," said Ed Jones, vice president of operations for The Methodist Hospital Research Institute. "Researchers at Methodist will be able to do live imaging studies that give them crucial information about how and where infections are progressing. This is what can happen when the best scientists and engineers from academia and industry become partners in advancing the state of the art in medical technology."

Methodist will be the sole practical test site for the development of the technology.

The purpose of the suite is to study pathogens that require biosafety level 3 (BSL-3) containment. BSL-3 pathogens include the bacteria that cause tuberculosis.

"This imaging facility will be the first of its kind," said James M. Musser, M.D., Ph.D., chair of the Department of Pathology and Laboratory Medicine and director of the Center for Molecular and Translational Human Infectious Diseases Research at The Methodist Hospital. "Our facility will permit us to translate critical new discoveries into the clinic, permitting accelerated development of novel diagnostic strategies and assessment of new therapeutic agents and vaccines."

King Li said the notion that imaging techniques might be used to shield populations from epidemiological harm is nearly a decade old.

"After 9/11 and the SARS outbreak in southeast Asia, the NIH wanted to build a BSL-4 imaging suite for studying infectious agents, both natural and bioterrorism-related," Li said. "I was at the NIH at the time, and helped design the imaging equipment for that facility."

Li's work with Philips led to two pending imaging patents.

A containment vessel will keep the subjects -- initially model organisms -- isolated from the unexposed space around it. Each vessel, or imaging cell, is accompanied by an external life support device on a transport trolley. The trolley is also used to maneuver the subject into place for imaging.

One of the project's ultimate goals, Li said, is to develop a similar facility that is equipped to diagnose infectious diseases in a large influx of (human) patients.

"If the partnership with Philips is successful, The Methodist Hospital Research Institute can take the next steps toward creating the only clinic in the world expressly designed to image patients with infectious agents, such as multi-drug-resistant TB," Li said. "This will allow for medical centers in the world to be more prepared for emerging diseases and bioterrorism."

The specific systems provided by Philips are the Ingenia 3T, Gemini TF 64, Precedence 16, and Veradius mobile C-arm.

Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a diversified health and well-being company. Headquartered in the Netherlands, Philips employs more than 120,000 employees with sales and services in more than 100 countries worldwide. With sales of EUR 22.3 billion in 2010, the company is a market leader in cardiac care, acute care and home health care, energy efficient lighting solutions and new lighting applications, as well as lifestyle products for personal well being and pleasure with strong leadership positions in male shaving and grooming, portable entertainment, and oral health care. News from Philips is located at the Philips newscenter website.

Follow Methodist on Facebook and Twitter